Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 12/20 | 1.00 |
| ▸ | CNOT7 | Q9UIV1 | 4/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | PARN | O95453 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960177 | 0.81 | FEN1 (0.69) | FEN1CNOT7PARNCA12CA9 | |
| SCHEMBL18670392 | 0.80 | FEN1 (1.00) | FEN1CA12CA9ERCC5ERCC1 | |
| SCHEMBL18670561 | 0.66 | FEN1 (1.00) | FEN1 | |
| SCHEMBL18688343 | 0.64 | FEN1 (1.00) | FEN1CA12CA9ERCC5ERCC1 | |
| SCHEMBL7969231 | 0.63 | FEN1 (0.45) | FEN1DAOCA9TSHRHSD17B10 | |
| SCHEMBL12909455 | 0.63 | FEN1 (0.45) | FEN1DAOCA9TSHRHSD17B10 | |
| SCHEMBL29959939 | 0.63 | FEN1 (0.69) | FEN1CA12CA9ERCC5ERCC1 | |
| SCHEMBL10833729 | 0.62 | ALDH1A1 (0.55) | FEN1DAOCA9TSHRHSD17B10 | |
| SCHEMBL18670563 | 0.62 | FEN1 (1.00) | FEN1CA12CA9ERCC5ERCC1 | |
| Benzylsulfonylbenzene SCHEMBL780337 | 0.61 | TSHR (0.68) | DAOCA9TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2022-02-22 | — | — | US | disclosed |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-07-30 | — | — | US | disclosed |
| WO-2017051251-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | FEN1, ERCC4, XPA | FEN1 1/4885CNOT7 2310/4885DAO 2346/4885 |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | FEN1, ERCC4, XPA | FEN1 1/4885CNOT7 2310/4885DAO 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.